Sanjaya Singh
Overview
Explore the profile of Sanjaya Singh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
678
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Venkataramani S, Ernst R, Derebe M, Wright R, Kopenhaver J, Jacobs S, et al.
Sci Rep
. 2020 Jun;
10(1):9722.
PMID: 32546687
Accelerated timelines necessitate the discovery of fully human antibodies as biotherapeutics using transgenic animals with a notion that such mAbs bypass humanization. A transgenic animal derived mAb (PCa75) targeted against...
12.
Tran Quang C, Zaniboni B, Humeau R, Lengline E, Dourthe M, Ganesan R, et al.
Blood
. 2020 Jun;
136(11):1298-1302.
PMID: 32483610
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy that accounts for ∼20% of ALL cases. Intensive chemotherapy regimens result in cure rates >85% in children and <50% in adults,...
13.
Nesspor T, Kinealy K, Mazzanti N, Diem M, Boye K, Hoffman H, et al.
Sci Rep
. 2020 May;
10(1):7557.
PMID: 32372058
Generation of bispecific antibodies (BsAbs) having two unique Fab domains requires heterodimerization of the two heavy chains and pairing of each heavy chain with its cognate light chain. An alternative...
14.
Low S, Wu H, Jerath K, Tibolla A, Fogal B, Conrad R, et al.
MAbs
. 2020 Jan;
12(1):1709322.
PMID: 31924119
CX3CR1 has been identified as a highly attractive target for several therapeutic interventions. Despite this potential, no potent antagonists, either small molecule or monoclonal antibody, have been identified. Here we...
15.
Vellalore Maruthachalam B, Zwolak A, Lin-Schmidt X, Keough E, Tamot N, Venkataramani S, et al.
MAbs
. 2020 Jan;
12(1):1708030.
PMID: 31906797
Mucosal immunity is dominated by secretory IgA and IgM, although these are less favorable compared to IgG molecules for therapeutic development. Polymeric IgA and IgM are actively transported across the...
16.
Yang D, Kroe-Barrett R, Singh S, Laue T
Antibodies (Basel)
. 2019 Sep;
8(1).
PMID: 31544830
Practically, IgG charge can contribute significantly to thermodynamic nonideality, and hence to solubility and viscosity. Biologically, IgG charge isomers exhibit differences in clearance and potency. It has been known since...
17.
Zheng C, Toth J, Bigwarfe T, MacDougall M, Jerath K, Bovat K, et al.
MAbs
. 2018 Sep;
10(8):1260-1268.
PMID: 30199300
Ang1 is a soluble ligand to receptor Tie2, and increasing the circulating Ang1 level may improve vascular stabilization under certain disease conditions. Here, we found that the circulating Ang1 level...
18.
Venkataramani S, Low S, Weigle B, Dutcher D, Jerath K, Menzenski M, et al.
Biochem Biophys Res Commun
. 2018 Aug;
504(1):19-24.
PMID: 30126632
Patients with severe Th2 type asthma often have a steroid resistant phenotype and are prone to acute exacerbations. Current novel therapies have only marginal therapeutic effects. One of the hypotheses...
19.
Yang D, Correia J, Stafford Iii W, Roberts C, Singh S, Hayes D, et al.
Protein Sci
. 2018 Apr;
27(7):1334-1348.
PMID: 29637644
Weak protein-protein interactions may be important to binding cooperativity. A panel of seven fluorescently labeled tracer monoclonal IgG antibodies, differing in variable (V) and constant (C) region sequences, were sedimented...
20.
Yang D, Kroe-Barrett R, Singh S, Roberts C, Laue T
MAbs
. 2017 Aug;
9(8):1231-1252.
PMID: 28812955
A central dogma in immunology is that an antibody's in vivo functionality is mediated by 2 independent events: antigen binding by the variable (V) region, followed by effector activation by...